BID (BH3-interacting domain death agonist) is a unique pro-apoptotic member of the BCL2 family that links the extrinsic (death receptor) and intrinsic (mitochondrial) pathways of apoptosis[^1]. BID is particularly important in neurons following various pathological insults including excitotoxicity, oxidative stress, and ischemia[^2].
The BID gene encodes a 195-amino acid protein that exists in both full-length (inactive) and truncated (active) forms. Proteolytic cleavage by caspases converts BID to its active form (tBID), which then translocates to mitochondria to initiate apoptosis[^3].
BID has a distinctive structure:
- N-terminal regulatory domain
- C-terminal BH3 domain (partially obscured)
- Requires proteolytic activation
- Generated by caspase-8 or caspase-3 cleavage
- Exposes the BH3 domain
- Trimerizes and localizes to mitochondria
- Highly potent at inducing apoptosis
¶ BH3 Domain
The BH3 domain (residues 80-120) mediates:
- Interaction with anti-apoptotic BCL2 proteins
- Direct activation of BAX/BAK
- Membrane targeting[^4]
BID serves as a bridge between death receptor and mitochondrial pathways:
- Extrinsic Pathway: Death receptor activation → caspase-8 → tBID
- Mitochondrial Pathway: tBID → BAX/BAK activation → cytochrome c release
- Amplification: Intrinsic pathway can further cleave BID
BID has roles beyond apoptosis:
- Mitochondrial dynamics regulation
- Autophagy modulation
- Cell cycle regulation
- Necroptosis regulation
In neurons, BID:
- Mediates excitotoxic cell death
- Participates in developmental pruning
- Responds to various stress signals[^5]
BID contributes to AD pathogenesis:
- Amyloid-beta triggers BID cleavage
- tBID levels increase in AD brains
- BID-mediated apoptosis contributes to neuronal loss
In PD:
- Mitochondrial dysfunction activates BID
- 6-OHDA and MPTP activate BID pathway
- BID deletion protects dopaminergic neurons
In motor neuron disease:
- Mutant SOD1 activates BID
- Excitotoxic insults trigger BID cleavage
- BID contributes to motor neuron apoptosis
BID is activated in ischemic brain injury:
- Cerebral ischemia cleaves BID
- tBID mediates infarct formation
- BID deficiency reduces damage[^6]
Therapeutic strategies include:
- Caspase inhibitors: Prevent BID activation
- BID BH3 mimetics: Blocking peptides
- Anti-apoptoticBCL2 activators: Sequester active BID
- Neuroprotective compounds: Prevent BID activation downstream
- Wang et al., BID structure and function (2001)
- Kantari et al., BID in apoptosis (2007)
- Merino et al., BID in neuronal death (2009)
- Singh et al., BID in stroke (2015)